Aktie R5W STEM CELL THERAPEUTICS CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Stem Cell Therapeutics Corp. Xetra

Aktien

R5W

CA8585721001

R5W

Schlusskurs Xetra
Andere Börsenplätze
- EUR - Intraday Chart für Stem Cell Therapeutics Corp.
2022 TCR2 Therapeutics ernennt Chief Business and Strategy Officer MT
2021 Pfizer strebt mit der 6,7-Milliarden-Dollar-Übernahme von Arena Pharmaceuticals ein erweitertes Know-how im Bereich der entzündlichen Erkrankungen an MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
TCR2 Therapeutics Appoints Chief Business and Strategy Officer
Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover
Pfizer scommette su promettente farmaco Arena con deal da 6,7 mld $
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index
Pfizer : a finalisé l'acquisition de Trillium Therapeutics
Trillium Therapeutics : Pfizer Completes Acquisition of Trillium Therapeutics - Form 8-K
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition
TRILLIUM THERAPEUTICS INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
Trillium Therapeutics Inc. Announces Executive Changes
Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer
Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval
Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.
TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)
Trillium: Q3 Earnings Snapshot
TRILLIUM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
North American Morning Briefing : Stock Futures -3-
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A12FG3 Aktie
  4. R5W Aktie
  5. Nachrichten Stem Cell Therapeutics Corp.
  6. Andere Sprachen